Metys Pharmaceuticals AG

Metys Pharmaceuticals is developing dimiracetam for the prevention of chemotherapy-induced painful peripheral neuropathy. In the US alone, in a single year, more than 400'000 patients suffer from the neuropathy caused by their life-saving cancer treatment. No drug has been approved to prevent or treat this condition. Dimiracetam is an orally active, small molecule with more than 200 patients' safety and tolerability data; dimiracetam is highly effective in preventing and treating chemotherapy-induced neuropathy in rodents. Metys Pharmaceuticals is preparing the first dedicated efficacy study of dimiracetam in this indication.